Zinzino
October 5, 2026
GOTHENBURG, Sweden -- October 5, 2026
Zinzino published a preliminary sales report showing group revenue for the third quarter of 2026 of 928.2 million Swedish kronor, up 18 percent from 784.1 million kronor a year earlier. Revenue from Zinzino sales markets rose 18 percent to 917.3 million kronor from 774.8 million kronor. External sales at Faun Pharma were 10.9 million kronor, up 17 percent from 9.3 million kronor.
September alone brought group revenue of 317.3 million kronor, up 16 percent from 274.5 million kronor. Zinzino sales-market revenue in September was 310.9 million kronor, up 15 percent, while Faun Pharma external sales were 6.4 million kronor, up 73 percent.
Accumulated revenue for January through September 2026 increased 21 percent to 2,787.1 million kronor from 2,302.2 million kronor. By region in the third quarter, North America rose 55 percent to 195.0 million kronor, South America nearly tripled to 10.1 million kronor, Asia-Pacific rose 48 percent to 95.1 million kronor and Central Europe rose 19 percent to 288.8 million kronor. East Europe declined 14 percent and the Baltics declined 13 percent, while the Nordics were down 3 percent.
The flash report covers sales by region and does not include profit figures. Zinzino is listed on Nasdaq First North Premier Growth Market and sells test-based nutrition products through direct sales distributors in more than 100 markets.